Does the media favor DNTH or GMAB?

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Genmab A/S. MarketBeat recorded 5 mentions for Dianthus Therapeutics and 3 mentions for Genmab A/S. Dianthus Therapeutics' average media sentiment score of 0.47 beat Genmab A/S's score of 0.00 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DNTH or ASND?

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 5 mentions for Dianthus Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.16 beat Dianthus Therapeutics' score of 0.47 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BBIO or DNTH?

In the previous week, BridgeBio Pharma had 8 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 5 mentions for Dianthus Therapeutics. BridgeBio Pharma's average media sentiment score of 0.86 beat Dianthus Therapeutics' score of 0.47 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DNTH or AXSM?

In the previous week, Axsome Therapeutics had 4 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 5 mentions for Dianthus Therapeutics. Axsome Therapeutics' average media sentiment score of 1.01 beat Dianthus Therapeutics' score of 0.47 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Axsome Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ELAN or DNTH?

In the previous week, Elanco Animal Health had 2 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 7 mentions for Elanco Animal Health and 5 mentions for Dianthus Therapeutics. Elanco Animal Health's average media sentiment score of 0.88 beat Dianthus Therapeutics' score of 0.47 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dianthus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dianthus Therapeutics (DNTH) Competitors

$87.53 +0.16 (+0.18%)

Closing price 04:00 PM Eastern

Extended Trading

$87.48 -0.06 (-0.06%)

As of 07:44 PM Eastern

Compare

DNTH vs. GMAB, ASND, BBIO, AXSM, and ELAN

Should you buy Dianthus Therapeutics stock or one of its competitors? MarketBeat compares Dianthus Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dianthus Therapeutics include Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does Dianthus Therapeutics compare to Genmab A/S?

Dianthus Therapeutics (NASDAQ:DNTH) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Genmab A/S has a net margin of 21.05% compared to Dianthus Therapeutics' net margin of -12,998.50%. Genmab A/S's return on equity of 15.34% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Genmab A/S	21.05%	15.34%	8.94%

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,345.72	-$162.34M	-$4.13	N/A
Genmab A/S	$3.90B	4.15	$963M	$1.32	19.65

In the previous week, Dianthus Therapeutics had 2 more articles in the media than Genmab A/S. MarketBeat recorded 5 mentions for Dianthus Therapeutics and 3 mentions for Genmab A/S. Dianthus Therapeutics' average media sentiment score of 0.47 beat Genmab A/S's score of 0.00 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dianthus Therapeutics currently has a consensus price target of $117.82, indicating a potential upside of 34.60%. Genmab A/S has a consensus price target of $37.93, indicating a potential upside of 46.22%. Given Genmab A/S's higher possible upside, analysts clearly believe Genmab A/S is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Dianthus Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Summary

Dianthus Therapeutics and Genmab A/S tied by winning 8 of the 16 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Dianthus Therapeutics (NASDAQ:DNTH) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Dianthus Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,345.72	-$162.34M	-$4.13	N/A
Ascendis Pharma A/S	$814.57M	18.27	-$258M	$8.67	27.52

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 5 mentions for Dianthus Therapeutics. Ascendis Pharma A/S's average media sentiment score of 1.16 beat Dianthus Therapeutics' score of 0.47 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Dianthus Therapeutics' net margin of -12,998.50%. Ascendis Pharma A/S's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Dianthus Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market.

Dianthus Therapeutics presently has a consensus price target of $117.82, indicating a potential upside of 34.60%. Ascendis Pharma A/S has a consensus price target of $295.39, indicating a potential upside of 23.81%. Given Dianthus Therapeutics' higher probable upside, research analysts plainly believe Dianthus Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Dianthus Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

BridgeBio Pharma currently has a consensus price target of $91.05, suggesting a potential upside of 32.66%. Dianthus Therapeutics has a consensus price target of $117.82, suggesting a potential upside of 34.60%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

BridgeBio Pharma has a net margin of -124.42% compared to Dianthus Therapeutics' net margin of -12,998.50%. BridgeBio Pharma's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Dianthus Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.77	-$724.93M	-$3.74	N/A
Dianthus Therapeutics	$2.04M	2,345.72	-$162.34M	-$4.13	N/A

In the previous week, BridgeBio Pharma had 8 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 5 mentions for Dianthus Therapeutics. BridgeBio Pharma's average media sentiment score of 0.86 beat Dianthus Therapeutics' score of 0.47 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BridgeBio Pharma beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Axsome Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Dianthus Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 4 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 9 mentions for Axsome Therapeutics and 5 mentions for Dianthus Therapeutics. Axsome Therapeutics' average media sentiment score of 1.01 beat Dianthus Therapeutics' score of 0.47 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dianthus Therapeutics currently has a consensus price target of $117.82, suggesting a potential upside of 34.60%. Axsome Therapeutics has a consensus price target of $258.95, suggesting a potential upside of 7.02%. Given Dianthus Therapeutics' higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dianthus Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,345.72	-$162.34M	-$4.13	N/A
Axsome Therapeutics	$638.50M	19.50	-$183.17M	-$3.73	N/A

Axsome Therapeutics has a net margin of -26.59% compared to Dianthus Therapeutics' net margin of -12,998.50%. Dianthus Therapeutics' return on equity of -27.30% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Summary

Axsome Therapeutics beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Dianthus Therapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Elanco Animal Health has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Dianthus Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Dianthus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.46	-$232M	-$0.50	N/A
Dianthus Therapeutics	$2.04M	2,345.72	-$162.34M	-$4.13	N/A

Elanco Animal Health has a net margin of -4.95% compared to Dianthus Therapeutics' net margin of -12,998.50%. Elanco Animal Health's return on equity of 7.42% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Elanco Animal Health presently has a consensus price target of $28.55, indicating a potential upside of 22.99%. Dianthus Therapeutics has a consensus price target of $117.82, indicating a potential upside of 34.60%. Given Dianthus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dianthus Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Elanco Animal Health had 2 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 7 mentions for Elanco Animal Health and 5 mentions for Dianthus Therapeutics. Elanco Animal Health's average media sentiment score of 0.88 beat Dianthus Therapeutics' score of 0.47 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dianthus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Elanco Animal Health beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Dianthus Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNTH vs. The Competition

Export

Metric	Dianthus Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.78B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-21.19	19.75	24.92	23.98
Price / Sales	2,345.72	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	7.67	8.29	10.79	6.50
Net Income	-$162.34M	$23.85M	$3.56B	$336.88M
7 Day Performance	10.97%	5.21%	1.67%	-0.22%
1 Month Performance	1.21%	2.19%	0.43%	0.77%
1 Year Performance	408.90%	60.99%	32.84%	31.57%

Dianthus Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNTH Dianthus Therapeutics	2.4154 of 5 stars	$87.53 +0.2%	$117.82 +34.6%	+418.5%	$4.78B	$2.04M	N/A	80
GMAB Genmab A/S	4.0239 of 5 stars	$24.74 +0.7%	$37.93 +53.3%	+21.0%	$15.33B	$3.72B	18.74	3,029	Analyst Forecast Options Volume
ASND Ascendis Pharma A/S	4.9172 of 5 stars	$231.20 +3.5%	$295.39 +27.8%	+28.9%	$13.93B	$814.57M	26.67	1,189	Positive News Analyst Downgrade
BBIO BridgeBio Pharma	3.4915 of 5 stars	$66.64 -2.0%	$89.14 +33.8%	+65.2%	$13.32B	$502.08M	N/A	400
AXSM Axsome Therapeutics	2.5181 of 5 stars	$251.91 -0.6%	$256.79 +1.9%	+146.2%	$13.04B	$638.50M	N/A	380	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DNTH) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. GMAB, ASND, BBIO, AXSM, and ELAN

How does Dianthus Therapeutics compare to Genmab A/S?

Summary

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Summary

How does Dianthus Therapeutics compare to Axsome Therapeutics?

Summary

How does Dianthus Therapeutics compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dianthus Therapeutics (DNTH) Competitors

DNTH vs. GMAB, ASND, BBIO, AXSM, and ELAN

How does Dianthus Therapeutics compare to Genmab A/S?

Is DNTH or GMAB more profitable?

Do institutionals and insiders believe in DNTH or GMAB?

Which has better valuation and earnings, DNTH or GMAB?

Does the media favor DNTH or GMAB?

Do analysts rate DNTH or GMAB?

Which has more risk and volatility, DNTH or GMAB?

Summary

How does Dianthus Therapeutics compare to Ascendis Pharma A/S?

Which has preferable earnings & valuation, DNTH or ASND?

Does the media favor DNTH or ASND?

Is DNTH or ASND more profitable?

Which has more volatility and risk, DNTH or ASND?

Do analysts recommend DNTH or ASND?

Do insiders and institutionals believe in DNTH or ASND?

Summary

How does Dianthus Therapeutics compare to BridgeBio Pharma?

Do analysts prefer BBIO or DNTH?

Is BBIO or DNTH more profitable?

Do institutionals & insiders have more ownership in BBIO or DNTH?

Which has more risk and volatility, BBIO or DNTH?

Which has higher earnings & valuation, BBIO or DNTH?

Does the media prefer BBIO or DNTH?

Summary

How does Dianthus Therapeutics compare to Axsome Therapeutics?

Which has more volatility & risk, DNTH or AXSM?

Does the media favor DNTH or AXSM?

Do analysts rate DNTH or AXSM?

Do institutionals & insiders have more ownership in DNTH or AXSM?

Which has better earnings and valuation, DNTH or AXSM?

Is DNTH or AXSM more profitable?

Summary

How does Dianthus Therapeutics compare to Elanco Animal Health?

Which has more volatility & risk, ELAN or DNTH?

Which has preferable earnings & valuation, ELAN or DNTH?

Is ELAN or DNTH more profitable?

Do institutionals and insiders believe in ELAN or DNTH?

Do analysts recommend ELAN or DNTH?

Does the media refer more to ELAN or DNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH vs. The Competition

Dianthus Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools